Objective: Endothelial progenitor cells (EPCs) have been examined in numerous adult diseases and have been suggested as a cellular-based therapy. However, there are no reports describing EPCs being isolated from newborn peripheral blood.
Introduction
Advances in the field of endothelial cell biology have provided techniques to quantify and culture endothelial progenitor cells (EPCs) from peripheral blood of adults since their original description of EPCs in 1997 by Asahara et al. 1 Recently, these techniques have been used to enumerate the number of EPCs from patients with adult diseases associated with endothelial cell dysfunction, including patients with cardiovascular disease and type 2 diabetes mellitus. [2] [3] [4] Furthermore, functional testing of EPCs isolated from patients with cardiovascular disease showed multiple defects in vitro compared with those isolated from healthy controls. 5 Thus, isolation of EPCs from patients with diseases associated with endothelial cell dysfunction provides a potential marker of disease progression.
Although techniques to isolate EPCs from adult peripheral blood are well established, it is unknown whether these methods can be used to isolate these cells from the peripheral blood of newborn infants. We have routinely isolated endothelial colony-forming cells (ECFCs), a subtype of EPCs, from adult peripheral blood, term and preterm umbilical cord blood. [6] [7] [8] [9] These cells have been shown to show the desired functional characteristics of an EPC, such as having a robust proliferative capacity, form secondary endothelial cell colonies and form vessels in vivo. 8 Given that ECFCs have been successfully harvested from adult peripheral blood and human umbilical cord blood using these techniques, it is likely that these methods can be used to isolate these cells from the peripheral blood of infants.
We used blood taken from extracorporeal membrane oxygenation (ECMO) circuits either at the time of circuit change or at decannulation as a source of a large quantity of peripheral newborn blood that can be sampled noninvasively. ECMO is a form of cardiopulmonary bypass used in critically ill term infants with severe lung injury. After completion of therapy, the remaining circuit contains a large amount of peripheral blood from the newborn, which is typically discarded.
Both term and preterm infants develop a number of diseases, which could be associated with endothelial cell dysfunction, including persistent pulmonary hypertension, cardiopulmonary complications from hypoxic injury and bronchopulmonary dysplasia. [10] [11] [12] [13] These diseases contribute greatly to the morbidity and mortality observed in neonatal intensive care units. Quantification of the number of ECFCs and study of the function of these cells compared with healthy controls will likely yield new and important information regarding the role of endothelial cells in the pathogenesis of these newborn diseases and their utility as a marker of either disease progression or morbidities. The presence of ECFCs in the peripheral blood of term infants has not previously been described. The objective of this project was to isolate ECFCs from critically ill term infants by collecting blood from ECMO circuits as a source of peripheral blood.
Methods
Studies were approved by the Institutional Review Board of Indiana University, and written informed consent was obtained from the parents. Consent was not obtained for one patient because the parents were not available. Thus, this sample was collected and analyzed per an approved protocol; however, no identifying patient information was collected. Study subjects included 12 term infants requiring ECMO and samples were taken from the ECMO circuit either at the time of a circuit change or at decannulation; two patients had samples taken with circuit change and at decannulation (n ¼ 14 samples). The clinical characteristics of the study subjects are summarized in Table 1 .
Culture of mononuclear cells from ECMO samples
Mononuclear cells (MNCs) were isolated from a buffy coat cell preparation by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ, USA), as described earlier. 6, 7 Briefly, blood samples (70 to 200 ml) were diluted 1:1 with Hank's balanced salt solution (Invitrogen, Grand Island, NY, USA) and overlaid onto an equivalent volume of Ficoll. Cells were centrifuged for 30 min at room temperature at 740 g. MNCs were isolated and washed three times with endothelial basal medium (EBM)-2 medium (Cambrex, Walkersville, MD, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 2% penicillin/ streptomycin (Invitrogen) and 0.25 mg ml -1 amphotericin B (Invitrogen) (complete EGM-2 medium). Cells were seeded onto separate wells of a six-well tissue culture plate precoated with type 1 rat tail collagen (BD Biosciences, Bedford, MA, USA) at 37 1C, 5% CO 2 , in a humidified incubator. After 24 h of culture, nonadherent cells and debris were aspirated, adherent cells were washed once with complete EGM-2 medium, and complete EGM-2 medium was added to each well. Medium was changed daily for 7 days and then every other day until the first passage.
Clonal isolation of two distinct colonies from newborn ECMO samples ECFCs were identified as well-circumscribed monolayers of cobblestone appearing cells and appeared in culture between days 7 and 14. A distinctly different colony type also appeared in half of the cultures between days 8 and 20 with the appearance of spindleshaped cells growing rapidly in a confluent wave-like pattern and phenotypically resembled mesenchymal stem cell (MSC) colonies. EFFC and presumed MSC colonies were identified by visual inspection with inverted microscopy (Olympus, Lake Success, NY, USA) and were isolated with cloning rings (Fisher Scientific, Hampton, NH, USA). Cells were released from the culture plate with 0.25% trypsin-EDTA (Invitrogen), resuspended in cEGM-2, and plated onto 75-cm 2 tissue culture flasks precoated with type 1 rat tail collagen, and cultured at 37 1C, 5% CO 2 , in a humidified incubator for further passage.
Immunophenotyping of ECFCs and MSCs
Early passage (1 to 2) ECFCs and MSCs were incubated with primary or isotype control antibody and analyzed by fluorescenceactivated cell sorting and Cell Quest software (Becton Dickinson, San Diego, CA, USA) as described earlier. 6, 7 We used primary murine monoclonal antibodies (all BD Pharmigen, San Diego, CA, USA unless otherwise indicated) directed against human CD31, CD45, CD14 and CD105 conjugated to fluorescein isothiocyanate; human CD73 and CD146 conjugated to phycoerythrin; human CD144 conjugated to Alexa Fluor 647; human CD54 and CD90 conjugated to allophycocyanin per manufacturer's 
Functional analysis of ECFCs
Matrigel assays were performed using early passage ECFC and MSC cells seeded onto 96-well tissue culture plates precoated with Matrigel (BD Biosciences) as described earlier. 6, 7 Cells were then serially observed by inverted microscopy over the next 24 h for capillary-like formation. MSCs and human umbilical vein endothelial cell lines were used as negative and positive controls.
To assess the ability to incorporate DiI-acetylated low-density lipoprotien (DiI-Ac-LDL), early passage ECFC and MSC cells were incubated with DiI-Ac-LDL (Invitrogen) as described earlier. 6 Cells were examined by fluorescence microscopy for uptake of DiI-Ac-LDL.
In vitro differentiation of MSCs
As we had a distinct colony-type phenotypically resembling MSCs that grew in culture with the ECFCs, we performed the following assays to test if the presumptive MSCs could differentiate into adipocytes and osteocytes using previously described methods. 14 Plates were examined under Â 50 magnification for positive red staining of lipid droplets.
To confirm osteogenic differentiation, differentiated MSCs and non-induced cells were cultured in six-well plates, washed with phosphate-buffered saline, and fixed in ice cold 70% ethanol (Sigma). Fixed cultures were washed with distilled water and stained for 30 min at room temperature with a 2% solution of alizarin red S (Sigma).
14 Plates were examined under Â 50 magnification for positive orange-red staining of calcium deposits.
Results
The objective of this study was to determine whether ECFCs could be isolated from peripheral blood of ECMO circuits of term infants. Samples from ECMO circuits were used as a source of newborn peripheral blood. Fourteen samples were obtained from 12 patients and ECFCs were cultured from all samples. ECFC colonies appeared between 7 and 14 days in culture at 9.4±8 per 10 7 MNCs. The ECFC colonies showed the typical appearance of endothelial progenitor colonies as well circumscribed, cobblestone monolayer of cells (Figure 1a) . ECFC colonies were clonally isolated and expanded in culture to provide sufficient number of endothelial cells for further analysis. Immunophenotyping results of these cells (Figure 1b) confirmed expression of endothelial cell antigens CD31, CD144, CD146 and CD105. Importantly, ECFCs did not express the hematopoietic cell surface antigens CD45 or CD14. We further tested whether the presumed ECFCs isolated would incorporate DiI-Ac-LDL and form capillary-like structures in Matrigel (Figures 1c and d, respectively) , two functional characteristics of endothelial cells. 6 ECFC cells did successfully update DiI-Ac-LDL and form capillary-like structures in Matrigels; however, cells from MSC colonies did not show these functional characteristics. Thus, these assays confirmed that the ECFCs isolated from the ECMO samples were endothelial in origin.
We unexpectedly found distinctly different colonies in 7 out of the 14 samples (subjects 2, 3, 5, 6, 7, 10 and 11), which had the morphology of spindle-shaped cells growing rapidly in a confluent wave-like pattern ( Figure 2a ) and hypothesized that these were MSC. These cells appeared between 8 and 20 days in of culture at a frequency of 1.4 ± 0.8 per 10
7 MNC. The presumed MSC colonies were also clonally isolated and expanded in culture as described above. Immunophenotyping (Figure 2b ) revealed these cells were positive for MSC cell surface markers CD54, CD73 and CD90. However, MSCs did not express the endothelial cell surface antigens CD31, CD144, CD146 and were also negative for the hematopoietic cell surface markers CD45 and CD14. Previous studies of MSC isolated from adults have shown that these cells can be differentiated into adipocytes, osteocytes and chrondrocytes. 15 Work from our lab has shown that when these cells are isolated from preterm cord blood they can also differentiate into these cell lineages as well. 7 Therefore, we set out to confirm that the presumed MSCs from the term peripheral blood could differentiate into adipocytes and osteocytes. We subjected the cells from the MSC colonies as well as appropriate positive and negative controls, to the differentiation experiments described above. The presumed MSC isolated from the ECMO samples did indeed differentiate into the expected cell types, which morphologically, histologically and cytochemically appeared to be adipocytes and osteocytes (Figures 2c and d) . Cells isolated from ECFC colonies did not show the same differentiation capabilities.
Discussion
ECFCs, a subset of EPCs, have been isolated from multiple sources, including adult peripheral and human term and preterm umbilical cord blood. [6] [7] [8] [9] The objective of this study was to use the remaining blood from ECMO circuits as a source of peripheral newborn blood to isolate ECFCs from critically ill term infants. ECFCs are cultured from the mononuclear fraction of blood and as the donor blood supplied to the circuit is only packed red blood cells with the mononuclear fraction removed, any stem cells present should be from the newborn. We successfully isolated ECFCs from the ECMO blood samples; however, we unexpectedly isolated MSCs from the same blood samples. To our knowledge, this is the first report of isolating either of these stem cells from peripheral blood of critically ill term newborns.
ECFCs were isolated from all patients and diagnoses groups (persistent pulmonary hypertension, congenital heart disease and congenital diaphragmatic hernia). There was no correlation between the type and number of colonies isolated and any clinical outcome, such as mortality, length of mechanical ventilation or length of oxygen therapy; however, this would be difficult to discern in such a small study. We found ECFC colonies at a frequency that was similar to the frequency we have reported with term umbilical cord blood; 7 although, the expected frequency of ECFCs in healthy newborns has not been determined.
Adult studies report an inverse correlation between number of EPCs and Framingham risk factor score, as well as a correlation to future adverse cardiovascular outcome. 2, 16 In fact, EPCs have been studied in clinical trials in adults as a cellular therapy for repair of damaged blood vessels. 17 However, 'EPC' has now become a nondescriptive term as many definitions are used to identify EPCs, although many different cell populations are actually being described. 18 We have focused on ECFCs for this study, which previously have been shown to show the functional characteristics of progenitor cells of endothelial origin, including possessing a high proliferative potential, expression of endothelial cell surface antigens but not hematopoietic cell surface antigens and clonally give rise to progeny that spontaneously form human blood vessels in vivo. 6, 8 There are many disease states encountered in the neonatal intensive care units that may be associated with vascular damage during acute illness or that may potentially alter vascular development in newborns; some examples include persistent pulmonary hypertension of the newborn, congenital diaphragmatic hernia, congenital heart disease, sepsis and Stem cells in critically ill newborns SJ Hoesli et al bronchopulmonary dysplasia. Therefore, the study of ECFCs in this population may provide new information on the pathogenesis of these illnesses and potentially a prognostic clinical tool. MSC were found in half of the ECMO samples and in all diagnoses groups. Again, there was no correlation to any clinical outcome. There is no consensus on the cell surface antigens, which should be used to identify MSC; however, adult studies have shown these cells to be capable to differentiate into chrondrocytes, adipocytes and osteocytes. 15 The presumptive MSC isolated in our ECMO blood samples expressed MSC cell surface markers CD54, CD73 and CD90. However, MSCs did not express the endothelial cell surface antigens and were also negative for the hematopoietic cell surface markers. In addition, these cells were able to be differentiated into adipocytes and osteocytes; thus, we are confident that the spindle-shaped cells we unexpectedly found in culture with the ECFCs were indeed MSCs. Our recently reported data from umbilical cord blood samples showed MSCs were more likely to be isolated in preterm cord blood and not found in term cord blood. 7 However, their presence in peripheral blood of critically ill term neonates requiring ECMO has not previously been reported.
Hennrick et al. 19 reported the presence of MSC found in 11 of 20 endotracheal tube aspirates from ventilated preterm infants with respiratory distress syndrome. In their small study, they noted a trend toward increase days on mechanical ventilation, days of oxygen supplementation and incidence of bronchopulmonary dysplasia in patients from which MSC were isolated and speculated that MSC could be a marker of neonatal lung injury; however, they admit no conclusions can be made without a much larger study powered to evaluate these outcomes. The adult literature suggests that mesenchymal cells may have a role in acute lung injury and persistent acute respiratory distress syndrome. [20] [21] [22] However, their role in neonatal lung injury has not been adequately analyzed. As ECMO is often used as a therapy for neonates with acute lung injury, our findings suggest MSCs may be isolated from newborns so to evaluate their role in the repair process of neonatal lung injury.
In conclusion, to our knowledge this is the first report of isolating ECFCs or MSCs in peripheral blood of critically ill term infants requiring ECMO. We speculate that both the ECFCs and MSCs isolated in this study could potentially have been recruited for many reasons; such as, from the procedure of ECMO cannulation, from response to critical illness or from an inflammatory response to the ECMO circuit or acute lung injury. During ECMO, the infant's blood is continuously exposed to the non-biologic synthetic surfaces of the ECMO circuit. In some patients, such exposure may cause activation of a systemic inflammatory reaction. 23, 24 We hypothesize that this could have resulted in the recruitment of multiple cell types, including endothelial and MSCs. Future studies are needed to describe expected frequency of ECFCs and MSCs in healthy term newborns as well as in critically ill neonates not requiring ECMO and to investigate their role in a variety of disease processes observed in neonates.
